{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T08:42:30Z","timestamp":1781599350874,"version":"3.54.5"},"reference-count":41,"publisher":"e-Century Publishing Corporation","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/rflg6657","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:01:57Z","timestamp":1762246917000},"page":"8143-8156","source":"Crossref","is-referenced-by-count":1,"title":["When Parkinson's disease encounters high fever: two case reports and literature review"],"prefix":"10.62347","volume":"17","author":[{"given":"Yi-Hui","family":"Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Simonet C, Tolosa E, Camara A and Valldeoriola F. Emergencies and critical issues in Parkinson’s disease. Pract Neurol 2020; 20: 15-25.","DOI":"10.1136\/practneurol-2018-002075"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10286-021-00801-w","article-title":"Dyskinesia-hyperpyrexia syndrome in Parkinson’s disease: a systematic review","volume":"31","author":"Wang","year":"2021","unstructured":"Wang M, Wang W, Gao Z, Yin X, Chen T, Jiang Z and Wang Z. Dyskinesia-hyperpyrexia syndrome in Parkinson’s disease: a systematic review. Clin Auton Res 2021; 31: 529-542.","journal-title":"Clin Auton Res"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1002\/mds.23255","article-title":"Dyskinesia-hyperpyrexia syndrome: another Parkinson’s disease emergency","volume":"25","author":"Gil-Navarro","year":"2010","unstructured":"Gil-Navarro S and Grandas F. Dyskinesia-hyperpyrexia syndrome: another Parkinson’s disease emergency. Mov Disord 2010; 25: 2691-2692.","journal-title":"Mov Disord"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1323717","DOI":"10.3389\/fneur.2023.1323717","article-title":"Dyskinesia-hyperpyrexia syndrome in Parkinson’s disease triggered by overdose of levodopa - a case report and literature review","volume":"14","author":"Du","year":"2024","unstructured":"Du X, Wang X and Geng X. Dyskinesia-hyperpyrexia syndrome in Parkinson’s disease triggered by overdose of levodopa - a case report and literature review. Front Neurol 2024; 14: 1323717.","journal-title":"Front Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"627","DOI":"10.5692\/clinicalneurol.cn-001740","article-title":"Dyskinesia-hyperpyrexia syndrome triggered by overdose of istradefylline: a case report","volume":"62","author":"Komori","year":"2022","unstructured":"Komori S, Tsuboi T, Suzuki M, Nakamura T and Katsuno M. Dyskinesia-hyperpyrexia syndrome triggered by overdose of istradefylline: a case report. Rinsho Shinkeigaku 2022; 62: 627-631.","journal-title":"Rinsho Shinkeigaku"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.5334\/tohm.912","article-title":"Dyskinesia-hyperpyrexia syndrome in Parkinson’s disease may benefit from GPi deep brain stimulation: a case report","volume":"15","author":"Huang","year":"2025","unstructured":"Huang SS, Ma LL, Sheng HS, Liu RP, Zhu SG, Xu SS, Sheng ML, Chen ZL, Zhang N, Zhang X and Wang JY. Dyskinesia-hyperpyrexia syndrome in Parkinson’s disease may benefit from GPi deep brain stimulation: a case report. Tremor Other Hyperkinet Mov (N Y) 2025; 15: 20.","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.parkreldis.2016.12.018","article-title":"Dyskinesia-hyperpyrexia syndrome under continuous dopaminergic stimulation","volume":"36","author":"Acebr&#xF3","year":"2017","unstructured":"Acebrón Sánchez-Herrera F, García-Barragán N, Estévez-Fraga C, Martínez-Castrillo JC and López-Sendón Moreno JL. Dyskinesia-hyperpyrexia syndrome under continuous dopaminergic stimulation. Parkinsonism Relat Disord 2017; 36: 103-104.","journal-title":"Parkinsonism Relat Disord"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1136\/jnnp-2017-315985","article-title":"Dopamine dysregulation syndrome in Parkinson’s disease: a systematic review of published cases","volume":"88","author":"Warren","year":"2017","unstructured":"Warren N, O’Gorman C, Lehn A and Siskind D. Dopamine dysregulation syndrome in Parkinson’s disease: a systematic review of published cases. J Neurol Neurosurg Psychiatry 2017; 88: 1060-1064.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Lin MT, Ho MT and Young MS. Stimulation of the nigrostriatal dopamine system inhibits both heat production and heat loss mechanisms in rats. Naunyn Schmiedebergs Arch Pharmacol 1992; 346: 504-510.","DOI":"10.1007\/BF00169004"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Lin MT, Chandra A, Tsay BL and Chern YF. Hypothalamic and striatal dopamine receptor activation inhibits heat production in the rat. Am J Physiol 1982; 242: R471-481.","DOI":"10.1152\/ajpregu.1982.242.5.R471"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1001\/archneur.64.1.141","article-title":"Presynaptic mechanisms of motor complications in Parkinson disease","volume":"64","author":"Fuente-Fern&#xE1","year":"2007","unstructured":"de la Fuente-Fernández R. Presynaptic mechanisms of motor complications in Parkinson disease. Arch Neurol 2007; 64: 141-143.","journal-title":"Arch Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.neuroscience.2017.06.023","article-title":"Heat stress-induced neuroinflammation and aberration in monoamine levels in hypothalamus are associated with temperature dysregulation","volume":"358","author":"Chauhan","year":"2017","unstructured":"Chauhan NR, Kapoor M, Prabha Singh L, Gupta RK, Chand Meena R, Tulsawani R, Nanda S and Bala Singh S. Heat stress-induced neuroinflammation and aberration in monoamine levels in hypothalamus are associated with temperature dysregulation. Neuroscience 2017; 358: 79-92.","journal-title":"Neuroscience"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.parkreldis.2019.05.018","article-title":"Dyskinesia-Hyperpyrexia Syndrome in Parkinson’s disease with Deep Brain Stimulation and high-dose levodopa\/carbidopa and entacapone","volume":"64","author":"Novelli","year":"2019","unstructured":"Novelli A, Di Vico IA, Terenzi F, Sorbi S and Ramat S. Dyskinesia-Hyperpyrexia Syndrome in Parkinson’s disease with Deep Brain Stimulation and high-dose levodopa\/carbidopa and entacapone. Parkinsonism Relat Disord 2019; 64: 352-353.","journal-title":"Parkinsonism Relat Disord"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1152\/jn.00066.2005","article-title":"Temperature sensitivity of dopaminergic neurons of the substantia nigra pars compacta: involvement of transient receptor potential channels","volume":"94","author":"Guatteo","year":"2005","unstructured":"Guatteo E, Chung KK, Bowala TK, Bernardi G, Mercuri NB and Lipski J. Temperature sensitivity of dopaminergic neurons of the substantia nigra pars compacta: involvement of transient receptor potential channels. J Neurophysiol 2005; 94: 3069-3080.","journal-title":"J Neurophysiol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.pnpbp.2010.09.014","article-title":"Sunshine-exposure variation of human striatal dopamine D(2)\/D(3) receptor availability in healthy volunteers","volume":"35","author":"Tsai","year":"2011","unstructured":"Tsai HY, Chen KC, Yang YK, Chen PS, Yeh TL, Chiu NT and Lee IH. Sunshine-exposure variation of human striatal dopamine D(2)\/D(3) receptor availability in healthy volunteers. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 107-110.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.5692\/clinicalneurol.55.182","article-title":"Dyskinesia-hyperpyrexia syndrome in a patient with Parkinson’s disease: a case report","volume":"55","author":"Taguchi","year":"2015","unstructured":"Taguchi S, Niwa J, Ibi T and Doyu M. Dyskinesia-hyperpyrexia syndrome in a patient with Parkinson’s disease: a case report. Rinsho Shinkeigaku 2015; 55: 182-184.","journal-title":"Rinsho Shinkeigaku"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Petrulli JR, Kalish B, Nabulsi NB, Huang Y, Hannestad J and Morris ED. Systemic inflammation enhances stimulant-induced striatal dopamine elevation. Transl Psychiatry 2017; 7: e1076.","DOI":"10.1038\/tp.2017.18"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1212\/WNL.53.1.91","article-title":"Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study","volume":"53","author":"Blanchet","year":"1999","unstructured":"Blanchet PJ, Fang J, Hyland K, Arnold LA, Mouradian MM and Chase TN. Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study. Neurology 1999; 53: 91-95.","journal-title":"Neurology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1234974","DOI":"10.3389\/fneur.2023.1234974","article-title":"Case report: reversible encephalopathy caused by dyskinesia-hyperpyrexia syndrome","volume":"14","author":"Luo","year":"2023","unstructured":"Luo B, Zhang H and Qin L. Case report: reversible encephalopathy caused by dyskinesia-hyperpyrexia syndrome. Front Neurol 2023; 14: 1234974.","journal-title":"Front Neurol"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Sarchioto M, Ricchi V, Melis M, Deriu M, Arca R, Melis M, Morgante F and Cossu G. Dyskinesia-hyperpyrexia syndrome in Parkinson’s disease: a heat shock-related emergency? Mov Disord Clin Pract 2018; 5: 534-537.","DOI":"10.1002\/mdc3.12663"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/00005053-198105000-00011","article-title":"Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs","volume":"169","author":"Toru","year":"1981","unstructured":"Toru M, Matsuda O, Makiguchi K and Sugano K. Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs. J Nerv Ment Dis 1981; 169: 324-327.","journal-title":"J Nerv Ment Dis"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Azar J, Elinav H, Safadi R and Soliman M. Malignant deep brain stimulator withdrawal syndrome. BMJ Case Rep 2019; 12: e229122.","DOI":"10.1136\/bcr-2018-229122"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Azar J, Jaber Y, Ayyad M, Abu Alia W, Owda F, Sharabati H, Zeid H, Khreshi S, AlBandak M and Sayyed Ahmad D. Parkinsonism-hyperpyrexia syndrome: a case series and literature review. Cureus 2022; 14: e29646.","DOI":"10.7759\/cureus.29646"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/NRL.0000000000000330","article-title":"Parkinsonism-hyperpyrexia syndrome after amantadine withdrawal: case report and review of the literature","volume":"26","author":"Dos Santos","year":"2021","unstructured":"Dos Santos DT, Imthon AK, Strelow MZ, Pille A and Schumacher-Schuh AF. Parkinsonism-hyperpyrexia syndrome after amantadine withdrawal: case report and review of the literature. Neurologist 2021; 26: 149-152.","journal-title":"Neurologist"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0002-9343(99)00329-0","article-title":"Neuroleptic malignant-like syndrome in an elderly patient caused by abrupt withdrawal of tolcapone, a-catechol-o-methyl transferase inhibitor","volume":"108","author":"CU","year":"2000","unstructured":"Iwuagwu CU, Riley D and Bonoma RA. Neuroleptic malignant-like syndrome in an elderly patient caused by abrupt withdrawal of tolcapone, a-catechol-o-methyl transferase inhibitor. Am J Med 2000; 108: 517-518.","journal-title":"Am J Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.4103\/psychiatry.IndianJPsychiatry_113_18","article-title":"Parkinsonism-hyperpyrexia syndrome: a case report and review of literature","volume":"60","author":"Grover","year":"2018","unstructured":"Grover S, Sathpathy A, Reddy SC, Mehta S and Sharma N. Parkinsonism-hyperpyrexia syndrome: a case report and review of literature. Indian J Psychiatry 2018; 60: 499-503.","journal-title":"Indian J Psychiatry"},{"key":"ref26","unstructured":"Díaz Castela M, Prendes Fernández P, Heres Bruck S, Suárez San Martín E, García Fernández C, Sol Álvarez J, Lozano Aragoneses B, Sáiz Ayala A, Santamarta Liébana E, Álvarez Carriles J, González Álvarez L and Blázquez Estrada M. Parkinsonism-hyperpyrexia, a rare consequence of deep brain stimulator malfunction in advanced Parkinson’s disease. Clin Park Relat Disord 2024; 10: 100246."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.3233\/JPD-223362","article-title":"Parkinsonism-hyperpyrexia syndrome and dyskinesia-hyperpyrexia syndrome in Parkinson’s disease: two cases and literature review","volume":"12","author":"Wang","year":"2022","unstructured":"Wang JY, Huang JF, Zhu SG, Huang SS, Liu RP, Hu BL, Zhu JH and Zhang X. Parkinsonism-hyperpyrexia syndrome and dyskinesia-hyperpyrexia syndrome in Parkinson’s disease: two cases and literature review. J Parkinsons Dis 2022; 12: 1727-1735.","journal-title":"J Parkinsons Dis"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Harada T, Mitsuoka K, Kumagai R, Murata Y, Kaseda Y, Kamei H, Ishizaki F and Nakamura S. Clinical features of malignant syndrome in Parkinson’s disease and related neurological disorders. Parkinsonism Relat Disord 2003; 9 Suppl 1: S15-23.","DOI":"10.1016\/S1353-8020(02)00124-4"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Kuno S, Mizuta E and Yamasaki S. Neuroleptic malignant syndrome in parkinsonian patients: risk factors. Eur Neurol 1997; 38 Suppl 2: 56-59.","DOI":"10.1159\/000113484"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/mds.870040408","article-title":"“On-off”-induced lethal hyperthermia","volume":"4","author":"Pfeiffer","year":"1989","unstructured":"Pfeiffer RF and Sucha EL. “On-off”-induced lethal hyperthermia. Mov Disord 1989; 4: 338-341.","journal-title":"Mov Disord"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1212\/WNL.35.2.258","article-title":"Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause","volume":"35","author":"Fig&#xE0","year":"1985","unstructured":"Figà-Talamanca L, Gualandi C, Di Meo L, Di Battista G, Neri G and Lo Russo F. Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause. Neurology 1985; 35: 258-261.","journal-title":"Neurology"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1007\/s00415-015-7956-4","article-title":"Parkinsonism-hyperpyrexia syndrome and deep brain stimulation","volume":"262","author":"Artusi","year":"2015","unstructured":"Artusi CA, Merola A, Espay AJ, Zibetti M, Romagnolo A, Lanotte M and Lopiano L. Parkinsonism-hyperpyrexia syndrome and deep brain stimulation. J Neurol 2015; 262: 2780-2782.","journal-title":"J Neurol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3389\/fneur.2019.00652","article-title":"Infectious etiologies of parkinsonism: pathomechanisms and clinical implications","volume":"10","author":"Limphaibool","year":"2019","unstructured":"Limphaibool N, Iwanowski P, Holstad MJV, Kobylarek D and Kozubski W. Infectious etiologies of parkinsonism: pathomechanisms and clinical implications. Front Neurol 2019; 10: 652.","journal-title":"Front Neurol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s12028-008-9125-4","article-title":"The parkinsonism-hyperpyrexia syndrome","volume":"10","author":"EJ","year":"2009","unstructured":"Newman EJ, Grosset DG and Kennedy PG. The parkinsonism-hyperpyrexia syndrome. Neurocrit Care 2009; 10: 136-140.","journal-title":"Neurocrit Care"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"20542704221086162","DOI":"10.1177\/20542704221086162","article-title":"An unwell patient with Parkinson’s disease: hyperpyrexia syndrome in a heatwave","volume":"13","author":"Mooney","year":"2022","unstructured":"Mooney E, Smith MD and Henderson EJ. An unwell patient with Parkinson’s disease: hyperpyrexia syndrome in a heatwave. JRSM Open 2022; 13: 20542704221086162.","journal-title":"JRSM Open"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1176\/ajp.142.10.1137","article-title":"Neuroleptic malignant syndrome","volume":"142","author":"Levenson","year":"1985","unstructured":"Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142: 1137-1145.","journal-title":"Am J Psychiatry"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Zhao J, Xu G, Feng C, Chen Y, Kang Y, Liu F and Ma W. Trihexyphenidyl induced malignant hyperthermia in a patient with Parkinson’s disease complicated with pneumonia: a case report. Medicine (Baltimore) 2020; 99: e20129.","DOI":"10.1097\/MD.0000000000020129"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1017\/S109285291200003X","article-title":"Practical guide for prescribing MAOIs: debunking myths and removing barriers","volume":"17","author":"Grady","year":"2012","unstructured":"Grady MM and Stahl SM. Practical guide for prescribing MAOIs: debunking myths and removing barriers. CNS Spectr 2012; 17: 2-10.","journal-title":"CNS Spectr"},{"key":"ref39","unstructured":"Foong AL, Grindrod KA, Patel T and Kellar J. Demystifying serotonin syndrome (or serotonin toxicity). Can Fam Physician 2018; 64: 720-727."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/qjmed\/hcg109","article-title":"The Hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity","volume":"96","author":"Dunkley","year":"2003","unstructured":"Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH and Whyte IM. The Hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003; 96: 635-642.","journal-title":"QJM"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/10\/ajtr0165710.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T02:51:54Z","timestamp":1769136714000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/10\/ajtr0165710.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/rflg6657","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}